Research

NEW ORLEANS --The quest for an Ebola treatment is picking up speed. Federal officials have unveiled a plan to test multiple drugs at once, in an umbrella study with a single comparison group to give fast answers on what works.

"This is novel for us" and is an approach pioneered by cancer researchers, said Dr. Luciana Borio, head of the U.S. Food and Drug Administration's Ebola response. "We need to learn what helps and what hurts" and speed treatments to patients, she said.

She outlined the plan Wednesday at an American Society of Tropical Medicine and Hygiene conference in New Orleans....

Everyone in the umbrella study would get supportive care, such as intravenous fluids, then be assigned to receive one of several drugs or be in a comparison group. That's needed because without one, there's no way to know if any problems or deaths are from the drug or the disease, Cox said....

                                                                     Nov. 6, 2014

...a WHO-coordinated retrospective study, published in the New England Journal of Medicine, provides evidence that supportive care, especially rehydration and correction of metabolic abnormalities, may contribute to patient survival.

The study analysed clinical data on 37 confirmed Ebola patients admitted for treatment at hospitals in Conakry, Guinea’s capital and most densely populated city.

The cases occurred during the first month of West Africa’s first outbreak of Ebola virus disease. Fourteen of the patients were heath care workers. The majority (12) acquired their infection in a health care setting.

The majority (65%) of patients were male, countering assumptions that women, who are more likely to provide home care for patients and prepare bodies for funerals and burials, are more frequently exposed and infected.

To replace fluids lost through severe diarrhoea, 36 patients (97%) received oral rehydration solution. Additional intravenous fluid resuscitation was given to 28 (76%) patients.

Read complete press release

By Todd Ackerman                                                                           Nov. 5, 2014

... researchers at the University of Texas-Austin have developed a nasal spray vaccine that has protected monkeys against the deadly Ebola virus even a year after immunization.

The vaccine, a genetically engineered cold virus containing a tiny portion of Ebola DNA, saved 100 percent of monkeys who got a single spray through the nose in a new UT study. Injecting the vaccine only saved the lives of about 50 percent.

"The main advantage is the long-lasting protection after a single inhaled dose," Maria Croyle, a  professor of pharmaceutics and the study's principal investigator, said in a statement. "This is important since the longevity of other vaccines for Ebola (hasn't been) fully evaluated....

TORONTO GLOBE AND MAIL                               Nov. 3, 2014
By Kelly Grant
Canada is spending another $30.5-million to fight Ebola, but Ottawa is still not answering pleas from international aid organizations for medical personnel to care for the ill in West Africa.

The bulk of the money announced on Monday – $23.5-million – will be spent on testing a Canadian vaccine and an experimental therapy, ZMapp, both of which were developed largely at the National Microbiology Lab in Winnipeg....

A lab technician at the National Microbiology Lab in Winnipeg, Manitoba November 3, 2014.
(LYLE STAFFORD/THE CANADIAN PRESS)

Canada has so far dispatched two mobile laboratories with rotating teams of scientists to rapidly diagnose or rule out Ebola in Sierra Leone.

But Ottawa has been reluctant to send medical staff to West Africa because the government cannot guarantee they could be airlifted out if they fall ill.